PuSH - Publikationsserver des Helmholtz Zentrums München

Baroni, M.L.* ; Sanchez Martinez, D.* ; Gutierrez Aguera, F.* ; Roca Ho, H.* ; Castella, M.* ; Zanetti, S.* ; Velasco Hernandez, T.* ; Diaz de la Guardia, R.* ; Castaño, J.* ; Anguita, E.* ; Vives, S.* ; Nomdedeu, J.* ; Lapillone, H.* ; Bras, A.E.* ; van der Velden, V.H.J.* ; Junca, J.* ; Marin, P.* ; Bataller, A.* ; Esteve, J.* ; Vick, B. ; Jeremias, I. ; Lopez, A.* ; Sorigue, M.* ; Bueno, C.* ; Menendez, P.*

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.

J. Immunother. Cancer 8:e000845 (2020)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherapies for patients with refractory or relapse (R/R) AML are challenging because of the absence of a universal pan-AML target antigen and the shared expression of target antigens with normal hematopoietic stem/progenitor cells (HSPCs), which may lead to life-threating on-target/off-tumor cytotoxicity. CD33-redirected and CD123-redirected CARTs for AML are in advanced preclinical and clinical development, and they exhibit robust antileukemic activity. However, preclinical and clinical controversy exists on whether such CARTs are myeloablative. Methods We set out to comparatively characterize in vitro and in vivo the efficacy and safety of 41BB-based and CD28-based CARCD123. We analyzed 97 diagnostic and relapse AML primary samples to investigate whether CD123 is a suitable immunotherapeutic target, and we used several xenograft models and in vitro assays to assess the myeloablative potential of our second-generation CD123 CARTs. Results Here, we show that CD123 represents a bona fide target for AML and show that both 41BB-based and CD28-based CD123 CARTs are very efficient in eliminating both AML cell lines and primary cells in vitro and in vivo. However, both 41BB-based and CD28-based CD123 CARTs ablate normal human hematopoiesis and prevent the establishment of de novo hematopoietic reconstitution by targeting both immature and myeloid HSPCs. Conclusions This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Cell Engineering ; Immunotherapy ; Adoptive ; T Lymphocytes; Acute Myeloid-leukemia; Chimeric Antigen Receptor; Acute Myelogenous Leukemia; Mesenchymal Stem-cells; Xenograft Models; Chemotherapy; Cd123; Immunotherapy; Expression; Patient
ISSN (print) / ISBN 2051-1426
e-ISSN 2051-1426
Zeitschrift Journal for ImmunoTherapy of Cancer
Quellenangaben Band: 8, Heft: 1, Seiten: , Artikelnummer: e000845 Supplement: ,
Verlag BioMed Central
Verlagsort London
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)